Billionaire Profile
Phillip Frost
Global Rank
#1783

Image: MGHusf | CC0 | via Wikimedia Commons

Phillip Frost

CEO, Pharmaceuticals
UNITED STATES
Real-Time Net Worth
$2.318B
Estimated based on Pharmaceuticals stock value as of March 6, 2026
-0.76% (24h)
Age
89
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
UNITED STATES

Biography

Phillip Frost is an American entrepreneur, physician, and investor, renowned for his significant contributions to the pharmaceutical industry. Born in 1936, Frost's career spans decades marked by innovation, strategic investments, and philanthropic endeavors. His wealth stems primarily from his ventures in the healthcare sector, notably through his leadership roles in companies like Key Pharmaceuticals, Ivax Corporation, and OPKO Health. With an estimated net worth of $2.2 billion as of 2024, Frost's career began in academia and public service before transitioning into the business world. Frost is known for his strategic vision and ability to identify and nurture promising ventures, solidifying his status as a prominent figure in the medical technology field.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life and Education

Phillip Frost was born in the United States in 1936. He earned a B.A. in French Literature from the University of Pennsylvania in 1957 and an M.D. from the Albert Einstein College of Medicine in 1961. He also studied at the University of Paris from 1955 to 1956.

Rise to Success

Frost's career began in the public health sector and academia. He served as a lieutenant commander in the U.S. Public Health Service at the National Cancer Institute from 1963 to 1965. He later became a professor of dermatology at the University of Miami School of Medicine from 1966 to 1972 and served as the chairman of the dermatology department at Mount Sinai Medical Center in Miami Beach from 1972 to 1990. His entrepreneurial journey began in 1972 when he co-founded Key Pharmaceuticals, which was later sold to Schering-Plough in 1986 for $835 million. Frost's share was $100 million, which he used to found Ivax Corporation in 1987. Ivax was later sold to Teva Pharmaceuticals in 2006 for $7.6 billion.

Key Business Strategies

Frost is recognized for his strategic investments and his ability to identify and capitalize on opportunities within the healthcare industry. He has a history of acquiring, restructuring, and selling companies, significantly increasing his wealth over time. His current focus is on OPKO Health, a diversified healthcare company with interests in diagnostics, therapeutics, and strategic investments.

Philanthropy

Phillip Frost and his wife, Patricia, are known for their extensive philanthropic work. They have donated generously to various causes, including STEM programs, the University of Miami, the Frost Science Museum, and the Frost School of Music. Their contributions reflect a commitment to education, science, and the arts.

Career Milestones

1963

Lieutenant Commander

Served in the U.S. Public Health Service at the National Cancer Institute.

1966

Professor of Dermatology

Began as a professor of dermatology at the University of Miami.

1972

Co-founded Key Pharmaceuticals

Co-founded Key Pharmaceuticals.

1987

Founded Ivax Corporation

Founded Ivax Corporation.

2007

CEO and Chairman of OPKO Health

Became CEO and Chairman of OPKO Health.

Philanthropy & Social Impact

Education

University of Miami

$100M

Donations to science, technology, engineering, and mathematics programs.

Education

Frost School of Music

$33M

Contribution to the music program at Florida International University.

Science & Technology

Frost Science Museum

$45M

Support for the Phillip and Patricia Frost Museum of Science.

Business Philosophy & Leadership

Notable Quotes

"I was interested in a specialty that would permit me the time to reflect... I knew that surgery could never be for me because you're tied up in operating rooms most of the time. And I needed the freedom to do things."

Leadership Principles

Strategic Vision

Identifying and capitalizing on opportunities in healthcare.

Investment in Innovation

Focusing on new projects, and ways of developing new drugs.

Controversies & Challenges

2018

SEC Charges

Accused of participating in a "pump-and-dump" scheme, which was later settled.